Pharmacokinetics and bio-distribution are crucial factors affecting the performance of an intravenous drug. In this study, we explore the combined use of glucose and polyethylene glycol (PEG) ligands to further improve gold nanoparticle (GNP) pharmacokinetics and bio-distribution, with the aim of using the drug for in-vivo radiotherapy. The inclusion of PEG was found to significantly prolong the half-life period, where PEG-Glu-GNPs achieved 6 17 ± 3 71 h, compared to 1 23 ± 0 14 h for Glu-GNPs and 1 07 ± 0 22 h for uncoated GNPs. Our data indicates that nanoparticle size impacts cell uptake performance, with 20 nm being the optimal diameter for cancer treatment applications. Although PEG-GluGNPs mainly distributed in the spleen, liver, lung, and kidneys, the concentration of PEG-Glu-GNPs in tumour tissue was 20 times higher than healthy cells in the uterus and ovaries, reaching 9 22±2 41 g/g cancer tissue at 48 h after injection. This difference in uptake holds promise for selective tumor targeting which can in turn lead to more effective radiotherapy through the interaction of X-rays and GNPs. Specifically tumor size after 47 days of treatment had reduced to (769 ± 92) mm 3 compared to (1432 ± 269) mm 3 using X-rays alone and (3514 ± 1818) mm 3 without any treatment. Moreover, the mice remained healthy without statistically significant weight loss. Results of our pharmacokinetic and bio-distribution study as well as therapeutic data for PEG-Glu-GNPs in our tumor bearing animal model demonstrate that PEG-Glu-GNPs provide excellent in-vivo stability, tumor targeting function, and radiotherapeutic enhancement effects, providing useful insights for further clinical studies.
INTRODUCTION
Cervical cancer is the second most deadly gynecological malignancy in women worldwide, arising as a malignant neoplasm from cells in the cervix uteri. 80-85% of cervical cancers are squamous cell carcinomas while 15% are adenocarcinoma. [1] [2] [3] Typical treatments for cervical cancer include surgery, radiotherapy, chemotherapy, or their combination. Radiotherapy ranks among the most effective curative measures for uterine cervical cancer since squamouscancer cells are highly sensitive to ionizing radiation which damages DNA thereby initiating cell apoptosis. While early stage cervical cancer is largely curable by radiotherapy alone, complications arise in advanced cases where clinical results indicate the 5-year survival rate declines from 30-55% for patients in stage IIIB to only 4-20% for those in stage IVA. [4] [5] [6] New strategies are needed which increase radiation sensitivity of tumor cells while limiting total dose in surrounding healthy tissues to a minimum. Solid tumors have the property of Enhanced Permeability and Retention (EPR) of macromolecules and lipids, by which certain sizes of molecules, such as nanoparticles, liposomes, and macromolecular drugs, tend to accumulate in tumor tissue at much greater concentrations than in normal tissue. 7 8 To use the advantage of this cancer selective character, a number of efforts have been made by researchers to modify gold nanoparticles (GNPs) for targeted delivery to tumor sites. GNPs have also been studied for their potential as in-vivo radiation sensitizers to enhance CT-imaging contrast [9] [10] [11] [12] [13] [14] [15] and increase radiation absorption in cancer tissues. [16] [17] [18] [19] [20] [21] Moreover, gold nanoparticles are biocompatible and easily functionalized by various surface molecules to fortify their stability and increase targeted uptake by cancer cells. Several such engineered multifunctional GNPs were reported to be used for detecting tumour-specific (v) 3 expression, 22 anticancer drug delivery 23 and cancer molecular imaging. 24 However, a specifically designed GNP can only be used for one type of cancer. Glucose bound GNPs in this article are more universal and are able to be used for different types of cancers. Results from our previous in-vitro study indicate that binding thio-glucose to GNPs (Glu-GNPs) greatly enhances GNP uptake by cancer cells over normal tissue on account of elevated metabolic demands inherent to cancer. Glu-GNPs provided a 1.3-2.0 fold enhancement in radiotherapeutic growth inhibition compared to naked (citrate coated) GNPs when used to treat ovarian, prostate, and breast cancers. [16] [17] [18] The reason why glucose was chosen to cap gold nanoaprticles (Glu-GNPs) is that glucose is a basic nutrient and taken up by glucose-metabolizing cells such as brain, kidney and cancer cells. By binding thioglucose on GNPs' surfaces, these cells uptake the glucose along with GNPs attached. In addition, cancer cells undergo much faster metabolism than surrounding normal cells, therefore much more Glu-GNPs enter SiHa cervical squamous cell carcinoma cells than normal cells. The full potential of GNPs in clinical application is limited due to premature uptake by the reticuloendothelial system and subsequent accumulation in liver, kidneys, and spleen. To overcome this constraint, the water-soluble biocompatible polymer polyethylene glycol (PEG) was bound to GNPs. 25 26 In this study, we bound PEG in addition to glucose, forming PEGGlu-GNPs. Together, these two ligands ensure elevated GNP uptake by cancer tissue while increasing dose efficiency and decreasing the accumulation in normal tissues and organs.
In this in vivo pharmacokinetic study, we investigated the absorption, distribution, metabolism, and excretion (ADME) of PEG-Glu-GNPs, with particular emphasis on distribution which implicates targeting efficiency and the subsequent fate of GNPs. Although a number of studies have reported accumulation of GNPs within the tumor, liver, lung and spleen, 20 26-34 we go further to investigate the metabolism and excretion of PEG-Glu-GNPs. Balb/c nude mice were used to build a SiHa tumor model through which we monitor the bio-distribution, toxicity, excretion, and radio-therapeutic enhancement effect of PEG-Glu-GNPs.
MATERIAL AND METHODS

Chemicals and Materials:
All commercially available reagents and solvents were obtained from Sigma-Aldrich Chemical Corp. and Fisher Scientific Inc. They were used without further purification.
Cell cultures: SiHa (ATCC number: HTB-35), a cervical squamous cell carcinoma, was routinely cultured in Minimum Essential Medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS, GIBCO). Cells were cultured in water jacketed CO 2 incubators (Thermo Fisher Scientific Forma ® Series II, USA) at 37 C with 95% (v/v) air and 5% (v/v) CO 2 in a humidified atmosphere.
Animals: We used both Wistar rats and Balb/c nude mice in our experiments. All the animal care and experimental procedures have been reviewed and approved by the animal ethics and care committee at Shandong University, China. The animals were maintained in a specific pathogen-free environment and cared for in accordance with the institutional animal care guidelines.
Wistar rats: Female Wistar rats 6-8 weeks old, with an average body weight ranging 180-200 g were purchased from the Laboratory Animal Center of Shandong University (Jinan, China).
Balb/c nude mice and tumor bearing mouse model: Female Balb/c nude mice, 4 to 6 weeks old, weighing 20 g on average were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Science (Beijing, China). All mice were fed under specific pathogen-free (SPF) conditions for acclimatization, lasting at least one week by as per the institutional animal care guidelines. For the tumor bearing mouse model, 3 5 × 10 6 SiHa cells in 0.1 ml PBS buffer were subcutaneously injected to the right axillary of each mouse. The tumor grew for 10 to 15 days after injection. The tumor volume (V ) was calculated by V = 0 5 * a * b 2 where a is the major axis of the tumor, and b is the minor axis, both measured by vernier caliper. When a has reached 6-8 mm, and b is about 4-6 mm, corresponding to an overall tumor size of 100-150 mm 3 , the mice could be grouped for experimental studies.
PEG-Glu-GNPs: Based on previous studies, 26 we aimed for monodisperse GNPs 20 nm in diameter ensuring optimal in-vivo bio-compatibility. PEG-Glu-GNPs used for the in-vivo experiments were prepared in the following three stages: (i) Synthesis of GNPs: 20.0 mL of 2.075 mM chloroauric acid trihydrate (HAuCl 4 · 3H 2 O) was refluxed at 385 C on a magnetic hotplate (Fisher Scientific) while being stirred at 1200 rpm. Upon the initial descent of condensed liquid from the reflux column (indicative of boiling), 4.7 mL of 34 mM trisodium citrate was rapidly added to the solution (3.85:1 molar ratio of citrate:gold), initiating the reduction of cationic gold (pale yellow) to discrete spherical nanocrystal cores (dark red). Dicarboxyacetone (DCA), a byproduct of citrate reduction clings electrostatically to the gold surface, generating steric repulsion against aggregation. A scan across spectroscopic absorbance (300 nm-800 nm) using UV-vis (Thermo Scientific Evolution-60) reveals a distinct absorption peak at 518 nm, characteristic of plasmon resonance by gold nanoparticles approximately 20 nm in diameter. Particle size distribution (by number) is confirmed by dynamic light scattering (Malvern Nano-ZS) to average 19.27 nm across a unimodal peak (Fig. 1) . Citrate stabilized nanoparticles provide an intermediate platform for further functionalization.
(ii) Functionalization of GNPs: The surfaces of GNPs were functionalized using the ligands glucose and Figure 1 . Schematic diagram showing how PEG-Glu-GNPs can enhance cancer radiotherapy: Both thio-glucose (A) and PEG (B) were coated on GNPs to form PEG-Glu-GNPs (C). The size of the GNPs characterized by UV-vis spectrum was about 20 nm (D). According to the AFM image, the morphology of the GNPs coated with PEG is close to an oval shape (70 nm × 100 nm) with uniform hydrodynamic radius (E). The surface atom composition of the GNPs and Au S bond (F) were assessed by Kratos Axis 165 X-ray photoelectron spectroscopy (XPS). The PEG-Glu-GNPs had an improved biodistribution (G) and increased cancer tissue uptake (H) in vivo, this resulted in enhanced cancer radiotherapy (I). polyEthyleneGlycol (PEG), which selectively target cancer cells and enhance in-vivo stability respectively. Strong covalent bonding to gold surfaces is achieved through the nucleophilic thiol (-SH) substituent. Thiol-PEG was used as received while Thio-sodium-glucose (Glu-S-Na) was reacted with cation exchange resin (Marathon Dowex C) to capture Na + ions while releasing H + in-situ, forming thiol-glucose (Glu-SH).
Functionalization is accomplished via a two-step mechanism driven by competing affinities to bind with the gold nanoparticle surface. First, an influx of thiol compounds overpowers the weak electrostatic interaction between dicarboxyacetone and gold, causing the former to dislodge, leaving a vacancy for several covalent bonds to form. However, thiol ligands are more inclined to dismantle the surface of additional GNPs than overcome the energy barrier for covalent bonding, therefore ligands are provided in excess of binding sites by a factor of ten (∼ 1 8 × 10 18 ) to increase the thermodynamic likelihood for rapid saturation of exposed surfaces before particles have a chance to aggregate. The total number of binding sites can be approximated as: Arguably thiol-glucose is more important, as a ligand proven to enhance cancer cell targeting. It binds to gold in compact hexagonal units. Meanwhile PEG-5000 delivers functional stability through its long polymer backbone spanning over 300 atoms, and adheres to the gold surface obliquely, like long strands of hair anchored by the thiol linkage. The size of GNPs was characterized using a UVvis spectrum. The maximum absorbance was at 525 nm, and the size distribution in Figure 1 (D) shows that the average size of PEG-Glu-GNPs was about 20 nm. According to the AFM image ( Fig. 1(E) ), the morphology of the GNPs coated with PEG seems close to an oval shape (70 nm × 100 nm) with uniform hydrodynamic radius. Compared to GNPs, which have a size of 20 nm, the increased size of PEG-Glu-GNPs resulted from the added PEG layer. The surface atom composition of the GNPs was assessed by Kratos Axis 165 X-ray photoelectron spectroscopy (XPS), Au S bond on GNPs was measured (see Fig. 1(F) ). Too much PEG will block off binding sites and/or cover up already bound glucose to hinder molecular recognition. Therefore, glucose molecules are provided in 10:1 excess, with PEG formulated at the minimum concentration necessary for functional stability. (iii) Purifying and concentrating PEG-Glu-GNPs: Fractional separation of suspended solids is accomplished by centrifugation of samples at 10,000 rpm for 30 minutes. This generates a dense pellet and a pale supernatant. To maximize product recovery, the supernatant is recursively centrifuged two additional times, allowing additional pellet to be collected.
Characterizing tumor uptake of GNPs: Fresh tumor tissues were collected before or after undergoing either 1, 7, or 21 days of the radiotherapy. The tumor tissues were cut into 1-mm 3 slices and fixed with 2.5% glutaraldehyde. The fixed tissues were dehydrated in serial concentrations of ethanol and subsequently pure ethanol. The tissues were then treated with propylene oxide and Epon mixture (soaked overnight) and embedded in capsules with Epon mixture at 60 C for 24 hours. The sections were examined with a JEM-2000EX electron microscopy.
Pharmacokinetic study: Wistar rats were used for a pilot study. Sixteen rats were randomly divided into four groups (four in each group). The three experimental groups were treated with either uncoated GNPs, Glu-GNPs, or PEGGlu-GNPs, at a dosage of 0.75 mg gold per rat, injected through the tail vein. The remaining group of animals did not receive any treatment and served as the control. After designated time intervals: (5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, and 72 h), blood was collected from the rats through the ocular fundus venous plexus using the capillary pipette method. 1 ml of 20% HNO 3 was added into each blood sample to lyse the cells and GNPs to dissolve for 48 h. DI-water was used to dilute the blood sample proportionally. All samples were filtered using 0.22 m filter paper and ICP-AES was used to measure the gold concentration in each sample. The results were analyzed using DAS 2.1.1 software (Drug and Statistics version 2.1.1, Mathematical Pharmacology Professional Committee of China, Shanghai, China).
Four Balb/c female nude mice, 4-6 week old, each weighing 14-18 g were used for the second study. We injected PEG-Glu-GNPs once through the tail vein at a dosage of 0.2 ml (7.932 mg/ml) per mouse. The nude mice were anesthetized by ether inhalation first, after which the blood was collected from ocular fundus venous plexus by capillary pipette method. 0.1 mL of blood sample (about 2 droplets of blood) was collected each time at specific time points (5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h, and 96 h). Each sample was doused in 0.4 ml 20% HNO 3 for 24 h ensuring complete lysis, then filtered across 0.22 m filter paper. ICP-AES was used to measure gold concentration in each blood sample, then converted to total blood concentration of GNPs. DAS 2.1.1 software was used to analyze the results.
Bio-distribution and targeted uptake by cancer tissue: Three tumour bearing mice were allocated to be sacrificed at each of 12 time points to measure gold concentration in various organs. When the tumor diameter reached 6 to 8 mm, we injected PEG-Glu-GNPs via the tail vein at a dosage of 0.2 ml (7.932 mg/ml) per mouse. At different time points (5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h and 96 h), we sacrificed the mice and extracted their organs (heart, liver, spleen, lung, kidney, muscle, ovary/uterus, celiac lymph node, tumor tissue, blood, and feces). Each sample was separately weighed then mixed with 1 ml 20% HNO 3 over a 24 h timespan for complete lysis. Deionized water was added to equilibrate the final volume of each sample to 3 ml, following which the sample was filtered with a 0.22 m membrane. The gold concentration in each sample was measured by ICP-AES.
Enhanced radiotherapeutic effects of gold-based nanoparticles: 16 nude mice were used in this study (summarized in Table I ). A vernier calliper was used to measure the major (a) and the minor (b) axis of tumor, while the tumor volume (V ) was calculated using V (mm 3 ) = 0 5 * a * b 2 . Measurements were taken prior to every X-ray radiation, twice per week on Monday and Friday. Tumor volume in each group was recorded as Mean ± SD. The curve of volume-time was used to compare the difference among the groups.
Statistical methods: Differences in the bio-distribution of PEG-Glu-GNPs in different tissues were compared by Student's T -test. Variation in radiotherapeutic effectiveness was evaluated by one-way analysis of variance (ANOVA), where differences in P value less than 0.05 was considered to be statistically significant.
RESULTS
Pharmacokinetic Study Results
The drug half-life times for PEG-Glu-GNPs, Glu-GNPs, and uncoated GNPs were 6 17 ± 1 71 h, 1 23 ± 0 14 h, and 1 07 ± 0 22 h, respectively (Fig. 2(A) ). PEGlayated nanoparticles endured significantly longer drug circulation Figure 2 . In-vivo pharmacokinetics of PEG-Glu-GNPs in mice and Wistar rats: (A) the drug half-life times for GNPs, GluGNPs and PEG-Glu-GNPs; (B) in-vivo pharmacokinetics of PEG-Glu-GNPs in mice; and (C) in-vivo pharmacokinetics of PEG-Glu-GNPs in Wistar rats (four mice and Wistar rats n = 4 were used in each experiment).
times. The results of this pilot study for both Wistar rats and nude mice are shown in Figures 2(B) and (C). The kinetic curves for blood concentration of PEG-Glu-GNPs were similar for both Wistar rats and the BALB/c nude mice, characterized by an initial phase of sharp decline during which PEG-Glu-GNPs are circulated to various tissues via the blood. Following rapid initial uptake PEGGlu-GNPs are distributed to various organs for a useful time window prior to being excreted by the reticuloendothelial system.
Bio-Distribution of PEG-Glu-GNPs in Animal Organs and Tumour Tissue
The concentration of PEG-Glu-GNPs in the blood dropped 93.06% from an initial 74 18 ± 4 15 mg/L (5 min after injection) to 5 15 ± 0 87 mg/L (12 h after injection). 72 hours after injection no detectable concentrations of gold remained in the blood. Meanwhile, gold concentrations accumulated in other organs, especially the liver and spleen, which showed increases of 700% (8 00 ± 1 03 ug/g to 55 58 ± 2 55 ug/g) and 1080% (9 61 ± 2 00 ug/g to 85 74 ± 7 95 ug/g) respectively over a 24 h period (refer to Fig. 3 ). The lungs, kidneys, and lymph nodes also showed increases in gold concentration by 2.93-fold, 2.63-fold, and 3.17-fold, respectively over a 24 h period. One month later, the gold concentration in the liver, the spleen, the lymph nodes, and tumor tissue were 50.13%, 78.60%, 31.34%, and 43.60% of their peak values, respectively. The rate at which organs clear PEG-Glu-GNPs was quite slow, especially in the spleen. The biodistributions for different sized nanoparticles in different mice organs were tested and the data is listed in the Table II. We have checked the effect of nanoparticle size and discovered that 20 nm is better in terms of biodistribution (refer to Table II) . Therefore, we selected 20 nm GNPs in our study. Physical properties of GNPs such as TEM images and detailed surface modifications have been reported in our other articles. 16-18 23 Here we only outline the surface functionalization and binding site calculation.
Enhanced Radiotherapeutic Sensitivity
Results for radiotherapeutic enhancement by PEG-GluGNPs on BALB/c nude mice are shown in Figure 4 . After Figure 4 (a). This suggests that in the absence of radiation, GNPs are relatively inert. Used with X-rays, PEG-GluGNPs significantly reduced tumour size to (769 ± 92) mm 3 after two months, compared to (1432 ± 269) mm 3 with X-ray alone and (3514 ± 1818) mm 3 without any treatment. The mice stayed healthy without additional weight loss beyond that of the tumour (refer to Fig. 4(b) ).
DISCUSSION
Pharmacokinetics of PEG-Glu-GNPs Plasma clearance (CL) was used to characterize the evacuation of PEG-Glu-GNPs from the bloodstream, given in units of L/h, by Plasma clearance = Total body rate of drug elimination Plasma concentration = dx/dt /C t CL is often defined as the plasma volume which is totally cleared of drug per unit of time, formally calculated as the ratio between the drug elimination and the corresponding reference concentration. 30 The measured CL value for PEG-Glu-GNPs is 0 003 ± 0 001 L/h. This value is small and indicates limited ability of the liver/kidney to eliminate GNPs.
One important factor that affects the GNP concentration in blood is the clearance rate of GNPs by the reticuloendothelial system and other clearance systems. The half-life time of a drug is directly related to the clearance speed of GNPs by these systems. The drug half-life times for PEG-Glu-GNPs, Glu-GNPs, and uncoated GNPs were 6 17±1 71 h, 1 23±0 14 h, and 1 07±0 22 h, respectively (refer to Fig. 2(A) ). This result indicates that the clearance time of PEGlayated GNPs was extended by about 5 hours compared to that of either Glu-GNPs or GNPs. In other words, PEG-Glu-GNPs have significantly longer drug circulation times. The results of this pilot study for both Wistar rats and nude mice are shown in Figures 2(B) and (C), respectively. The kinetic curves for blood concentration of PEG-Glu-GNPs were similar for both Wistar rats and the BALB/c nude mice, characterized by an initial phase of sharp decline when PEG-Glu-GNPs were circulated to various tissues via the blood. Following rapid initial uptake, PEG-Glu-GNPs were then distributed to various organs within a useful time window prior to being excreted by the reticuloendothelial system.
PEG-Glu-GNP Uptake by Animal Organs and Tumour Tissue
Glucose ligands enhanced cancer cell uptake of GNPs because tumor cells need more carbohydrates to facilitate accelerated metabolism. PEGylation improved the biodistribution of GNPs in vivo by suppressing uptake by the reticuloendothelial system (liver, spleen, kidney), thus increasing their effective blood concentration to allow more GNPs into the tumor tissue. Moreover, PEG is known to increase the stability of GNPs in the blood and increase the half life-time. 25 26 Our previous study 26 shows that glucose coating on top of the PEG coating can further improve breast tumor uptake 2.02 fold for PEGGNPs, 2.33 fold for Glu-GNPs and 6.09 fold for PEG-GluGNPs compared to surrounding connective and muscle tissues. Most important from a therapeutic perspective was that PEG-Glu-GNPs achieved uptake in uterus tumour tissues at a concentration 20 times higher than surrounding healthy cells (Fig. 5(A) ). Figure 5 (B) shows that the gold concentration reached a peak of 9 22 ± 2 41 g/g, 48 h after injection. Transmission electron microscopy (TEM) images show that GNPs were distributed in both the nucleus and cytoplasm (Figs. 5(C)-(E)). Excretion and Clearance of PEG-Glu-GNPs One pathway for PEG-Glu-GNPs to be discharged from mice is through the biliary tract, manifesting as traceable amounts of gold detected in the feces starting at 6 h after injection and persisting more than one month (Fig. 3) . Meanwhile, accumulation of PEG-Glu-GNPs in the kidney suggests that gold nanoparticles could be secreted through urine as well, as confirmed in other studies. 20 31 Clearance of PEG-Glu-GNPs and Potential Chronic Side Effects Although no significant acute toxicity was observed among animals in this study, 1 potential chronic side effects of long term GNP retention in animal organs should be considered. Pharmacokinetic data in this paper indicates slow clearance rate for GNPs, prolonging retention in organs. One month later after GNP injection, gold concentration in the liver, the spleen, the lymph nodes, and tumor tissue were 50.13%, 78.60%, 31.34%, and 43.60% of their peak values, respectively.
To our best knowledge, no effective methods have been reported to accelerate GNP clearance from organs in vivo, thus, the best way to overcome the problem, so far, is to decrease GNP uptake in each organ and increase specific uptake by tumor tissues. For instance, in this study, PEGylation of GNPs greatly improved their bio-distribution in vivo while decreasing accumulation in the liver and the spleen by 70.3%, and 52.1%, respectively. Meanwhile, coating GNPs with PEG and glucose increased gold concentration in cancer tissue by 108.8% over coating with glucose alone. 1 Ultimately, glucose and PEG coatings improve GNPs' radiotherapeutic efficiency while minimizing chronic toxicity in three ways: (1) integrating more GNPs into tumor tissue; (2) requiring less GNP dose due to greater specific uptake; (3) decreasing GNP accumulation in healthy organs and surrounding tissues.
Among our future endeavors are plans to test GNP induced toxicity to each organ. Figure 6 shows TEM images of cervical tumor tissues with or without PEG-Glu-GNP induced radiotherapy. After the tumour bearing mice were treated with PEG-Glu-GNPs alone, X-ray (8 Gy) alone, or both in combination, the cervical tumor tissues were examined by TEM imaging. Figure 6 (a) is an image of control tumour cells where chromatin is distributed evenly around the nucleus. The cell in the lower-right corner is relatively independent with a clearly distinguished cell membrane and two nuclei. X-ray irradiation (8 Gy) induced nuclear membrane distortion and chromatin subsequently became dense as shown in Figure 6 (b). After the tumour cells were treated by PEGGlu-GNPs (1.59 mg in 200 l) plus X-ray (8 Gy), we clearly see the chromatin become even denser and begin to aggregate (Figs. 6(c) and (d) ). Eventually, the nucleus becomes fragmented and cell shrinks. Figure 6 (e) reveals that the chromatin gets decomposed and the membrane of nucleus disappears. The cell shrinks and splits into at least three apoptotic bodies exhibiting fragmentation of condensed chromatin and some organelles (Fig. 6(e) ). In the surrounding region, we also find oval-shaped vesicles (autolysosomes) formed from the cell's cytoplasm subjected to enzymatic digestion. Increased formation of autolysosomes is thought to protect cells undergoing damage, in this case directly indicative of X-ray efficacy. From these observations, we can conclude that GNPs had a definite effect on cancer tissue via mechanisms which will be subject to further investigation.
PEG-Glu-GNPs Enhanced Radiotherapy
Future Work: Potential Application of PEG-Glu-GNPs to Image-Guided Radiotherapy Regardless how effectively interventional surgery and/or radio/chemotherapy are presumed to combat cancer, many patients experience metastatic relapse. A scrupulous presurgical assessment of metastasis is one important step in diminishing chances relapse. Not only can accurate monitoring of metastasis effectively guide treatment in patients, it also serves as an important prognostic factor. To detect cancer metastasis, lymph node biopsy is deemed the current gold standard diagnosis for patients. However, this invasive approach is not suitable for all patients because of procedural morbidity. Therefore, a crucial goal is to develop accurate, minimally invasive techniques for metastasis monitoring to improve long-term outcomes in patients. Standard clinical imaging modalities such as CT, MRI, Positron Emission Tomography (PET), and ultrasound can be categorized as structural imaging modalities to identify anatomical patterns and to provide basic information regarding tumor location, size and spread.
Positron Emission Tomography (PET) imaging modalities can be used to assess specific molecular targets. PET is a nuclear medicine imaging technique, producing 3-D images of functional processes in the body. 32 33 A molecule is first tagged with a positron emitting isotope
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Glucose increases GNP uptake by cancer tissue PET-guided radiotherapy (Typical isotopes include 11 18 F or ( 18 F)-fluoro-deoxy-Dglucose being the most clinically utilized.) These positrons annihilate with nearby electrons, emitting two photons in opposite directions. By detecting these photons, the PET scanner can estimate the density of positron annihilations in a specific area. The foremost advantage of PET imaging over the other imaging modalities is its functional sensitivity of 10 −11 mol/L to 10 −12 mol/L, much better than MRI imaging. Our previous bio-distribution results show that glucose induces greater uptake of PEG-Glu-GNPs in cancer tissue, which is based on the same mechanism how PET imaging works. As a result, we can bind PEGGlu-GNPs with PET tracer ( 18 F)-fluoro-deoxy-D-glucose (FDG) to achieve PET-imaging guided cancer radiotherapy. Specifically, we can combine imaging and therapy in the same platform as shown in Figure 7 (refer to Ref. [34] for the detailed design).
CONCLUSION
In this article, we have shown that PEG-Glu-GNPs can enhance tumor uptake due to rapid glucose metabolism in cancerous tissue. Our in-vivo bio-distribution results show significantly increased gold concentration in cancer cells despite eventual retention of PEG-Glu-GNPs in the liver and spleen. Due to the elevated cellular uptake of PEG-Glu-GNPs by cancer cells versus surrounding normal tissue, we can achieve the same cancer killing effect with reduced irradiation dosage. As a result, surrounding healthy tissues are less exposed to ionizing radiation thus minimizing cell damage and side effects. Last but not least, we found PEG-Glu-GNPs were gradually secreted after two months. For our future research, we plan to bind PEG-Glu-GNPs with tumor specific biomarkers to achieve further targeted treatment.
